A Phase 2 extension study of donidalorsen, also known as IONIS-PKK-LRx, has been marked completed as of May 8, 2026. The trial, registered as NCT04307381, is titled "An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema." It evaluated donidalorsen in participants with hereditary angioedema during its extended phase.
The study status is listed as completed on ClinicalTrials.gov. This update reflects a change in trial status only. No results or outcome data are included in this event record.
Hereditary angioedema is a condition for which icatibant is an approved treatment. This trial update concerns a separate investigational agent, donidalorsen, studied in the same patient population. Readers should note that icatibant's approval status is unrelated to the completion of this donidalorsen extension study.
Further details on the trial design, enrollment, and any future data releases can be found through the official ClinicalTrials.gov listing. For background on icatibant itself, readers can consult the compound overview for additional context.